Sanofi

Elf Sanofi

Sonofi

Luciano Manara

Alberto Bianchetti

Tiziano Croci

Umberto Guzzi

Paolo Carminati

Roberto Cecchi

Dino Nisato

Antonina Giudice

Claude Moulineau

Roberto Sacilotto

The invention relates to 2-amino-7-hydroxytetralin carboxyalkyl ethers of formula ##STR1## wherein Alk represents a straight or branched (C.sub.3 -C.sub.5)alkylene group, and R is hydrogen or (C.sub.1 -C.sub.4)alkyl, useful as starting materials in the synthesis of 7-substituted phenylethanolaminotetralins of formula (XII) ##STR2## wherein X represents hydrogen, halogen, (C.sub.1 -C.sub.4)alkyl, or trifluoromethyl which are useful as spasmolytics and anti-glaucoma agents. The new 7-substituted phenylethanolaminotetralins (XII) as well as the intermediates in the preparation of the compounds (I), the N-protected 2-amino-7-hydroxytetralin carboxyalkyl ethers, are also claimed.

2-amino-7-hydroxytetralin carboxylalkyl ethers

A method of prophylaxis and/or treatment of intestinal motility disorders, in particular of constipation, in mammals which comprises administering to a mammal in need of such a treatment a prophylactically and/or therapeutically effective amount of a compound of formula (I) ##STR1## wherein Alk represents a straight or branched (C.sub.1 -C.sub.4)alkylene radical, and

Trifluoromethylphenyltetrahydropyridines for the treatment and/or

A method of prophylaxis and/or of treatment of ocular disorders, mainly of controlling intraocular hypertension and treating glaucoma, which comprises administering, preferably topically, a prophylactically and/or therapeutically effective amount of a phenylethanolamine derivative.

Pharmaceutical compositions for the treatment of ocular disorders

Phenylethanolamine analog active compounds, optionally substituted on the phenyl group with an halogen atom or with an alkyl or trifluoromethyl group and substituted on the amino group with a phenylalkyl or phenoxy alkyl group optionally substituted on the benzene ring, are used for the treatment and/or prophylaxis of gastrointestinal diseases associated with a smooth muscle contraction.

Phenylethanolamine analog active compounds for the treatment of

Methyllevallorphanium salts having peripheral antagonistic activity of formula ##STR1## wherein Y.sup.n(-) represents the anion a pharmaceutically acceptable acid other than halogen and n represents the number of negative charges of said anion; a process for their preparation by exchange of the halogen ion with the Y.sup.n(-) anion; and pharmaceutical compositions containing them as active ingredients.

Methyllevallorphanium salts having peripheral opiate antagonistic

The present invention relates to a pharmaceutical composition having a peripheral antagonistic action with respect to opiates containing, as active ingredient, a haloallylate of levallorphan of formula: ##STR1## where X is chlorine, bromine or iodine, mixed with a pharmaceutical excipient.

Growing community of inventors

Alessandria, Italy

Luciano Manara